GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Enovis Corp (NYSE:ENOV) » Definitions » Change In Receivables

ENOV (Enovis) Change In Receivables : $-61 Mil (TTM As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Enovis Change In Receivables?

Enovis's change in receivables for the quarter that ended in Mar. 2025 was $-16 Mil. It means Enovis's Accounts Receivable increased by $16 Mil from Dec. 2024 to Mar. 2025 .

Enovis's change in receivables for the fiscal year that ended in Dec. 2024 was $-57 Mil. It means Enovis's Accounts Receivable increased by $57 Mil from Dec. 2023 to Dec. 2024 .

Enovis's Accounts Receivable for the quarter that ended in Mar. 2025 was $436 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Enovis's Days Sales Outstanding for the three months ended in Mar. 2025 was 71.13.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Enovis's liquidation value for the three months ended in Mar. 2025 was $-1,597 Mil.


Enovis Change In Receivables Historical Data

The historical data trend for Enovis's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enovis Change In Receivables Chart

Enovis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.69 -110.99 -45.19 -16.32 -57.05

Enovis Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.01 -12.80 -4.38 -27.86 -15.98

Enovis Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enovis  (NYSE:ENOV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Enovis's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=435.618/558.834*91
=71.13

2. In Ben Graham's calculation of liquidation value, Enovis's accounts receivable are only considered to be worth 75% of book value:

Enovis's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=38.46-2254.816+0.75 * 435.618+0.5 * 585.911
=-1,597

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enovis Change In Receivables Related Terms

Thank you for viewing the detailed overview of Enovis's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Enovis Business Description

Traded in Other Exchanges
Address
2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Executives
John Kleckner officer: Principal Accounting Officer 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Berry Phillip Benjamin (ben) officer: SVP, Chief Financial Officer 2711 CENTERVILLE ROAD SUITE 400, WILMINGTON DE 19808
Rajiv Vinnakota director 8730 STONY POINT PARKWAY, SUITE 150, RICHMOND VA 23235
A Clayton Perfall director
Brady Shirley officer: EVP, Colfax, Pres. & CEO, DJO 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Patricia A Lang officer: SVP, Chief HR Officer C/O DIEBOLD NIXDORF, INCORPORATED, 5995 MAYFAIR ROAD, NORTH CANTON OH 44720
Bradley J Tandy officer: SVP, General Counsel P.O. BOX 587, 56 E. BELL DRIVE, WARSAW IN 46580
Daniel A Pryor officer: SVP??Strategy & Business Deve. DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Matthew L. Trerotola director, officer: President & CEO 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Christopher M Hix officer: SVP, Chief Financial Officer 2160 SATELLITE BLVD., SUITE 200, DULUTH GA 30097
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Christine Ortiz director 1200 ABERNATHY ROAD, NE, SUITE 1200, ATLANTA GA 30328
Angela S Lalor director 3M CENTER, BLDG. 0220-09-E-02, ST PAUL MN 55144 1000
Shyam Kambeyanda officer: ESAB President and SVP, Colfax 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Douglas J. Pitts officer: Controller, PAO 100 MATSONFORD ROAD, RADNOR PA 19087